Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages

Go Home

Supply Chain Options in Pharmaceuticals

Supply Chain Options in Pharmaceuticals

Nov 5, 2020 | Cases, Health Policy

A global pharmaceuticals company wanted to evaluate future supply-chain options for a group of drug products.

In a series of workshops held with knowledgeable personnel over a six week period, the team (comprising the modeller and all workshop attendees) developed a simple simulation to help understand the likely implications of organisational change involving a significant capital investment. The model centred on several aspects of the change, including co-location of a number of pharmaceutical production facilities and the possible impact of changes in the structure of the organisation on the ability of the supply chain to satisfy future customer demand while reducing overall stock levels. It had been thought that a simulation of the possible impact of moving from the AS-IS to the TO-BE organisation would help the decision-makers but that the traditional simulation approach used by the organisation would not be able to report in time for a major decision point in the investment project. The model’s results were reviewed at each stage and amendments made to reflect feedback from participants.

Final scenario runs included sensitivity analysis and presented the possible performance range of selected Key Performance Indicators.

The model was able to demonstrate the likely improvement in performance between the AS-IS and the TO-BE scenarios, both in stock reduction and in the reducing manufacturing cycle times and the conclusions were presented to senior decision-makers during their next meeting on the subject.

The work was completed in a short period of time and was vital to the correct investment of many millions of dollars that would not have been evident from conventional analysis.

The success was due to an effective synergy between the client and modeller; the former having the relevant expert knowledge and enthusiasm, the latter having considerable experience of pharmaceutical industry modelling.

Client Anonymous pharmaceutical company
Authors/Consultants Jones L (Ventana Systems UK)

Do you want to know more?

More Information

For more information on this case, please contact Lee Jones at Ventana Systems UK.


Credit Card Giant Halts Market Share Slide With Scenario Planning

Credit Card Giant Halts Market Share Slide With Scenario Planning The Problem MasterCard, a major credit card company, once held a dominant market position US Market Share with only one primary competitor, Visa. They woke up one day and realized that, after six years...

System Dynamics Helps Reduce Waiting Lines for NHS Patients

System Dynamics Helps Reduce Waiting Lines for NHS Patients EXECUTIVE Summary The impact of COVID-19 on the National Health Service (NHS) in England, led to growing record waiting lists, deterioration of patients and recovery of elective care became the number one...

Upcoming Events

Recent Posts

Multisolving Working With Complexity and Interconnection

Multisolving Working With Complexity and Interconnection Climate change. Biodiversity loss. Racial, gender, and economic inequity. Global pandemic and other health crises. Each of these challenges is serious on its own, but they also interact. Inaction on one crisis...

Join us

System Dynamics Admins
System Dynamics Admins